Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.53 |
| ▸ | SELP | P16109 | 1/20 | 0.50 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.45 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.45 |
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.40 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704299 | 0.96 | S1PR1 (0.48) | S1PR1S1PR3S1PR4S1PR5SELP | |
| SCHEMBL6510371 | 0.96 | S1PR1 (0.48) | S1PR1S1PR3S1PR4S1PR5SELP | |
| SCHEMBL4222844 | 0.90 | FABP3 (0.50) | S1PR1S1PR3S1PR4S1PR5SELP | |
| SCHEMBL4419953 | 0.90 | S1PR1 (0.47) | S1PR1S1PR3S1PR4S1PR5SELP | |
| SCHEMBL2622729 | 0.89 | SELP (0.53) | S1PR1S1PR3S1PR4S1PR5SELP | |
| SCHEMBL12272715 | 0.87 | S1PR1 (0.56) | S1PR1S1PR3S1PR4S1PR5GSTM2 | |
| SCHEMBL15500035 | 0.87 | S1PR1 (0.56) | S1PR1S1PR3S1PR4S1PR5GSTM2 | |
| SCHEMBL17240248 | 0.87 | S1PR1 (0.56) | S1PR1S1PR3S1PR4S1PR5GSTM2 | |
| SCHEMBL3424607 | 0.86 | PRKCA (0.55) | S1PR1S1PR3S1PR4S1PR5SELP | |
| SCHEMBL4407962 | 0.86 | SMN1; SMN2 (0.56) | S1PR1S1PR3S1PR4S1PR5SELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11692999-B2 | Method of screening ATP11C or CDC50A inhibitor | KYOTO UNIVERSITY (JP) | 2023-07-04 | — | — | US | disclosed |
| US-20230066723-A1 | MICROPARTICLE COMPOSITIONS | YEH JAMES SHUE MIN (GB) | 2023-03-02 | — | — | US | disclosed |
| US-20210311019-A1 | METHOD OF SCREENING ATP11C OR CDC50A INHIBITOR | KYOTO UNIVERSITY (JP) | 2021-10-07 | — | — | US | disclosed |
| US-11073510-B2 | Method of screening ATP11C or CDC50A inhibitor | KYOTO UNIVERSITY (JP) | 2021-07-27 | — | — | US | disclosed |
| EP-2934599-B1 | MICROPARTICLE COMPOSITIONS | YEH JAMES SHUE MIN (GB) | 2020-05-27 | — | — | EP | disclosed |
| EP-2890365-B1 | NANOPARTICLE FORMULATION | RES & INNOVATION UK (GB) | 2019-11-20 | — | — | EP | disclosed |
| US-20190242873-A1 | METHOD OF SCREENING ATP11C OR CDC50A INHIBITOR | KYOTO UNIVERSITY (JP) | 2019-08-08 | — | — | US | disclosed |
| EP-3130924-B1 | METHOD FOR SCREENING FOR INHIBITOR OF ATP11C OR CDC50A | UNIV KYOTO (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-10201499-B2 | Nanoparticle formulation | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2019-02-12 | — | — | US | disclosed |
| EP-3130924-A1 | METHOD FOR SCREENING FOR INHIBITOR OF ATP11C OR CDC50A | Kyoto University (JP) | 2017-02-15 | — | — | EP | disclosed |
| EP-2934599-A1 | MICROPARTICLE COMPOSITIONS | Yeh, James Shue-Min (GB) | 2015-10-28 | — | — | EP | disclosed |
| US-20150224054-A1 | NANOPARTICLE FORMULATION | IMPERIAL INNOVATIONS LTD (GB) | 2015-08-13 | — | — | US | disclosed |
| EP-2890365-A1 | NANOPARTICLE FORMULATION | Medical Research Council (GB) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014096859-A1 | MICROPARTICLE COMPOSITIONS | YEH JAMES SHUE-MIN (GB) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014033453-A1 | NANOPARTICLE FORMULATION | MEDICAL RESEARCH COUNCIL (GB) | 2014-03-06 | — | — | WO | disclosed |
| WO-2011098578-A2 | LIPOSOME SYSTEM FOR OCULAR ADMINISTRATION | BIONEER A/S (DK) | 2011-08-18 | — | — | WO | disclosed |
| US-7132122-B2 | Direct micro-patterning of lipid bilayers using UV light and selected uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-07 | — | — | US | disclosed |
| WO-2006104639-A2 | DEVICE COMPRISING ARRAY OF MICRO-OR NANO-RESERVOIRS | STANFORD UNIVERSITY (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2004111185-A2 | DIRECT MICRO-PATTERNING OF LIPID BILAYERS USING UV LIGHT AND SELECTED USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040180147-A1 | Direct micro-patterning of lipid bilayers using UV light and selected uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230066723-A1 | MICROPARTICLE COMPOSITIONS | PHOSPHO1, SGMS2, CHMP4B | S1PR1 287/4885S1PR3 168/4885S1PR4 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.